-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 11, 2024

Evaluating Value of BTK Inhibitors in CLL Treatment

Author(s)Ryan Haumschild, PharmD, MS, MBA, Roy Beveridge, MD, Brian T. Hill, MD, PhD

Experts evaluate the value of BTK inhibitors in CLL treatment.

Episodes in this series

A panel of 4 experts on CLL

EP. 1 Recent Trends and Innovations in the Management of CLL

A panel of 4 experts on CLL

EP. 2 CLL Treatment Landscape: Overview of BTK Inhibitors

A panel of 4 experts on CLL

EP. 3 Evaluating Value of BTK Inhibitors in CLL Treatment

A panel of 4 experts on CLL

EP. 4 Factors Influencing Choice of Second-Generation BTKi Monotherapy

A panel of 4 experts on CLL

EP. 5 Empowering Patients: Key Considerations for BTK Inhibitor Adherence

A panel of 4 experts on CLL

EP. 6 Optimizing Therapy Sequencing in CLL

A panel of 4 experts on CLL

EP. 7 Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

A panel of 4 experts on CLL

EP. 8 Decision-Making in CLL: The Role of Real-World Evidence

A panel of 4 experts on CLL

EP. 9 Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

A panel of 4 experts on CLL

EP. 10 Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

A panel of 4 experts on CLL

EP. 11 Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

A panel of 4 experts on CLL

EP. 12 The Inflation Reduction Act: Implications for Patient Access in CL

A panel of 4 experts on CLL

EP. 13 Patient Access Advocacy for BTK Inhibitors

A panel of 4 experts on CLL

EP. 14 Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Video content above is prompted by the following question(s):

How are payers evaluating the value of BTK inhibitors in the evolving treatment landscape of CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Kerry Rogers, MD

Easing Barriers to BTK Inhibitors in CLL: Kerry Rogers, MD

ByMaggie L. Shaw,Kerry Rogers, MD

July 8th 2026

Adam Kittai, MD

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

ByMaggie L. Shaw,Adam S. Kittai, MD

July 3rd 2026

Adam Kittai, MD

AV Gives CLL Patients a Fixed-Duration Oral Path: Adam Kittai, MD

ByMaggie L. Shaw,Adam S. Kittai, MD

June 29th 2026

Kerry Rogers, MD

Managing Toxicity, Sequencing for Long-Term BTKIs: Kerry Rogers, MD

ByMaggie L. Shaw,Kerry Rogers, MD

June 25th 2026

Zanubrutinib | Image Credit: © luchschenF-stock.adobe.com

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

ByMaggie L. Shaw

June 24th 2026

Trending on AJMC

Ebola Cases Top 1700 as Unpaid Health Workers Strike

FDA Approves Atacicept for IgA Nephropathy

FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6

Quest Adds Haystack MRD to OncoEMR for Community Oncology

Gene Therapy Could Ease Wet AMD's Injection Burden: Carl Regillo, MD